Targeting Homologous Recombination Repair in Cancer - DNA Repair in Cancer Therapy - page 150

128. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA
repair and recombination. Nat Rev Mol Cell Biol 2005;6(1):44 e 55.
129. Schild D, Wiese C. Overexpression of RAD51 suppresses
recombination defects: a possible mechanism to reverse genomic
instability. Nucleic Acids Res 2010;38(4):1061 e 70.
130. Willers H, Dahm-Daphi J, Powell SN. Repair of radiation damage
to DNA. Br J Cancer 2004;90(7):1297 e 301.
131. Powell SN, Kachnic LA. Therapeutic exploitation of tumor cell
defects in homologous recombination. Anticancer Agents Med
Chem 2008;8(4):448 e 60.
132. Hakem R, de la Pompa JL, Sirard C, et al. The tumor suppressor
gene Brca1 is required for embryonic cellular proliferation in the
mouse. Cell 1996;85(7):1009 e 23.
133. Suzuki A, de la Pompa JL, Hakem R, et al. Brca2 is required for
embryonic cellular proliferation in the mouse. Genes Dev 1997;
11(10):1242 e 52.
134. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in
breast and ovarian cancer pedigrees establish RAD51C as
a human cancer susceptibility gene. Nat Genet 2010;42(5):410 e 4.
135. Seal S, Thompson D, Renwick A, et al. Truncating mutations in
the Fanconi anemia J gene BRIP1 are low-penetrance breast
cancer susceptibility alleles. Nat Genet 2006;38(11):1239 e 41.
136. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes
a BRCA2-interacting protein, is a breast cancer susceptibility
gene. Nat Genet 2007;39(2):165 e 7.
137. Walsh T, King MC. Ten genes for inherited breast cancer. Cancer
Cell 2007;11(2):103 e 5.
138. D'Andrea AD. Susceptibility pathways in Fanconi's anemia and
breast cancer. N Engl J Med ; 362(20): 1909-19.
139. Merajver SD, Pham TM, Caduff RF, et al. Somatic mutations in
the BRCA1 gene in sporadic ovarian tumours. Nat Genet 1995;
9(4):439 e 43.
140. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in
primary breast and ovarian carcinomas. Science 1994;266(5182):
120 e 2.
141. Lancaster JM, Wooster R, Mangion J, et al. BRCA2 mutations in
primary breast and ovarian cancers. Nat Genet 1996;13(2):238 e 40.
142. Jones PA, Baylin SB. The fundamental role of epigenetic events in
cancer. Nat Rev Genet 2002;3(6):415 e 28.
143. Esteller M, Silva JM, Dominguez G, et al. Promoter hyper-
methylation and BRCA1 inactivation in sporadic breast and
ovarian tumors. J Natl Cancer Inst 2000;92(7):564 e 9.
144. Rice JC, Ozcelik H, Maxeiner P, Andrulis I, Futscher BW. Meth-
ylation of the BRCA1 promoter is associated with decreased
BRCA1 mRNA levels in clinical breast cancer specimens.
Carcinogenesis 2000;21(9):1761 e 5.
145. Catteau A, Harris WH, Xu CF, Solomon E. Methylation of the
BRCA1 promoter region in sporadic breast and ovarian cancer:
correlation with disease characteristics. Oncogene 1999;18(11):
1957 e 65.
146. Collins N, Wooster R, Stratton MR. Absence of methylation of
CpG dinucleotides within the promoter of the breast cancer
susceptibility gene BRCA2 in normal tissues and in breast and
ovarian cancers. Br J Cancer 1997;76(9):1150 e 6.
147. Potapova A, Hoffman AM, Godwin AK, Al-Saleem T, Cairns P.
Promoter hypermethylation of the PALB2 susceptibility gene in
inherited and sporadic breast and ovarian cancer. Cancer Res
2008;68(4):998 e 1002.
148. van der Groep P, Hoelzel M, Buerger H, Joenje H, de Winter JP,
van Diest PJ. Loss of expression of FANCD2 protein in sporadic
and hereditary breast cancer. Breast Cancer Res Treat 2007;107(1):
41 e 7.
149. Wei M, Xu J, Dignam J, et al. Estrogen receptor alpha, BRCA1,
and FANCF promoter methylation occur in distinct subsets of

sporadic breast cancers. Breast Cancer Res Treat 2008;111(1):
113 e 20.
150. Tokunaga E, Okada S, Kitao H, et al. Low incidence of methyl-
ation of the promoter region of the FANCF gene in Japanese
primary breast cancer. Breast Cancer ; 2009. Oct 8 [Epub ahead of
print].
151. Nakanishi K, Yang YG, Pierce AJ, et al. Human Fanconi anemia
monoubiquitination pathway promotes homologous DNA repair.
Proc Natl Acad Sci USA 2005;102(4):1110 e 5.
152. Godthelp BC, Wiegant WW, Waisfisz Q, et al. Inducibility of
nuclear Rad51 foci after DNA damage distinguishes all Fanconi
anemia complementation groups from D1/BRCA2. Mutat Res
2006;594(1 e 2):39 e 48.
153. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in
sporadic cancers. Nat Rev Cancer 2004;4(10):814 e 9.
154. Turner NC, Reis-Filho JS. Basal-like breast cancer and the BRCA1
phenotype. Oncogene 2006;25(43):5846 e 53.
155. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction
in sporadic basal-like breast cancer. Oncogene 2007;26(14):
2126 e 32.
156. Lambie H, Miremadi A, Pinder SE, et al. Prognostic significance
of BRCA1 expression in sporadic breast carcinomas. J Pathol 2003;
200(2):207 e 13.
157. Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neo-
adjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol
2010;28(7):1145 e 53.
158. Graeser M, McCarthy A, Lord CJ, et al. A marker of homologous
recombination predicts pathologic complete response to
neoadjuvant chemotherapy in primary breast cancer. Clin Cancer
Res 2010;16(24):6159 e 68.
159. Baldwin RL, Nemeth E, Tran H, et al. BRCA1 promoter region
hypermethylation in ovarian carcinoma: a population-based
study. Cancer Res 2000;60(19):5329 e 33.
160. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency
of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;
94(1):61 e 7.
161. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA,
DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in
ovarian cancer. J Natl Cancer Inst 2002;94(18):1396 e 406.
162. Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the
Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian
tumors. Nat Med 2003;9(5):568 e 74.
163. Kachnic LA, Li L, Fournier L, Willers H. Fanconi anemia pathway
heterogeneity revealed by cisplatin and oxaliplatin treatments.
Cancer Lett 2010;292(1):73 e 9.
164. Willers H, Kachnic LA, Luo C-M, et al. Biomarkers and mecha-
nisms of FANCD2 function. J Biomed Biotechnol 2008;8:821 e 9.
165. Pagano G, Degan P, d'Ischia M, et al. Oxidative stress as
a multiple effector in Fanconi anaemia clinical phenotype. Eur J
Haematol 2005;75(2):93 e 100.
166. Pagano G, Youssoufian H. Fanconi anaemia proteins: major roles
in cell protection against oxidative damage. Bioessays 2003;25(6):
589 e 95.
167. Hennessy BT, Timms KM, Carey MS, et al. Somatic mutations in
BRCA1 and BRCA2 could expand the number of patients that
benefit from poly (ADP ribose) polymerase inhibitors in ovarian
cancer. J Clin Oncol 2010;28(22):3570 e 6.
168. Hruban RH, Canto MI, Goggins M, Schulick R, Klein AP. Update
on familial pancreatic cancer. Adv Surg 2010;44:293 e 311.
169. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate
genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial
pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer
Res 2002;62(13):3789 e 93.